Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kingswood to delist from AIM as HSQ buys remaining stake

(Sharecast News) - Financial advice firm Kingswood Holdings has announced that majority shareholder HSQ Investments is to snap up all of the shares that it doesn't already own, giving shareholders the option of liquidity prior to delisting. Last week, HSQ raised its stake in the company from 68.4% to 89.39% by buying KPI's holding in the business. Now, HSQ intends to buy up the remaining shares and has requested to cancel Kingswood's AIM listing in a month's time.

The offer price, at 7p per share, is the same as last week's share purchase but follows a huge reduction in the share price over the past year.

HSQ, part of Pollen Street Capital, intends to merge Kingswood's UK and Ireland business with another Pollen Street wealth management company.

"HSQ considers that the offer provides Kingswood shareholders with the opportunity to realise their investment in the company for cash in a scenario where HSQ believes there is limited prospect of any future liquidity for the Kingswood shares," Kingswood said in a statement on Tuesday.

Kingswood's stock has halved since last summer as operations have been impacted by sector-wide headwinds, while its acquisition strategy has resulted in a big ramp up of debt over the past two years.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.